Description
An antilipolytic agent; inhibits lipolysis induced by noradrenaline and theophylline in rat epididymal adipocytes at 1 μM; decreases plasma free fatty acid levels in rats at 3 and 12 mg/kg; reduces plasma fatty acid concentration, the number of atherosclerotic plaques, and MMP-2 activity in ApoE-/- mice fed a palmitate-rich diet; reduces fasting blood glucose and plasma insulin levels as well as plasma free fatty acid and triglyceride levels in a rat model of streptozotocin-induced diabetes
Formal name: 5-methyl-2-pyrazinecarboxylic acid, 4-oxide
Synonyms:
Molecular weight: 154.1
CAS: 51037-30-0
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Lipids & Lipoproteins||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias